Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05607056
Other study ID # SPAADA202211_001
Secondary ID 2022-002817-40
Status Completed
Phase N/A
First received
Last updated
Start date November 27, 2022
Est. completion date April 25, 2023

Study information

Verified date December 2022
Source Neopharm Bulgaria Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of a probiotic, SINQUANON, on the reduction of the occurrence of diarrhea associated with antibiotic use in adults.


Description:

The study aims to evaluate the efficacy of a specialized multi-strain probiotic, SINQUANON, on the reduction of the incidence of antibiotic-associated diarrhea in adults and to demonstrate the benefit of administering the specialized multi-strain probiotic as a routine add-on to antibiotic therapy on prevention of antibiotic-associated diarrhea in adults who take antibiotics in the outpatient setting.


Recruitment information / eligibility

Status Completed
Enrollment 565
Est. completion date April 25, 2023
Est. primary completion date March 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Male or female subject aged 18 to 60 years. - The subject has given written informed consent after being provided orally with information about the study objective and design, including the administration regimen of the studied probiotic and the study procedures, the available safety data, as well as the rights and obligations of a participant. - The subject initiates oral antibiotic treatment in the ambulatory setting. - Acceptable antibiotic therapy: - Broad-spectrum penicillins - Cephalosporins - Quinolones - Tetracyclines Sequential administration of two antibiotics from the allowed groups is permitted, if the total duration of the antibiotic treatment does not exceed 10 days. - Planned duration of the antibiotic treatment of 5 to 10 days. - Body mass index (BMI) of 18.0 to 29.9 kg/m2 - In the opinion of the Investigator, the subject can adhere to the visit schedule, to be compliant with the trial treatment regimen and to complete the study. - The patient has a smartphone and can use it. Exclusion Criteria: - Antibiotics use within 60 days prior to randomization. - Daily consumption of probiotics, yogurt with probiotics and inability to stop this consumption. - Use of antidiarrheal medications, laxatives, enemas, or suppositories within 1 week prior to randomization and for the duration of the trial. - An episode of diarrhea within 30 days before screening, defined as =3 loose or liquid stools over 24 hours, regardless of the cause of the diarrhea. - Acute or chronic constipation - average number of formed stools <3 per week. - Allergy or hypersensitivity to any of the ingredients of the trial product. - Allergy or hypersensitivity to the antibiotic prescribed on Day 1. - Prior documented infection with Clostridioides difficile =3 months before screening. - History of chronic gastrointestinal conditions, including irritable bowel syndrome, chronic constipation, chronic diarrhea, dyspepsia, gastroesophageal reflux disease, diverticulitis, ulcerative colitis, Crohn's disease or any other abnormality in the absorption or gastrointestinal dysfunction. - Use of proton-pump inhibitors (PPIs) within 30 days prior to Day 1 and for the duration of the study. - Surgery to the intestines, artificial heart valve, history of rheumatological heart disease or infectious endocarditis within one year prior to screening. - Immunosuppressive therapy or any condition causing immunosuppression (including hematologic malignancies, AIDS, long-lasting corticosteroid treatment). - Planned administration of antibiotics, different from those acceptable for the study. - Patients in severe condition requiring urgent hospitalization or planned hospitalization during the study. - Planned administration of antibiotics >10 days. - BMI = 30 kg/m2. - Pregnant or lactating women; women who plan to get pregnant during the study. - Drug abuse or alcohol within the past year. - Unstable medical conditions, in the judgement of the Investigator. - Eating disorders (for example, anorexia, bulimia). - On a vegan diet. - Participation in a clinical trial within 60 days prior to randomization. - Inability to comply with the study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Sinquanon
This probiotic food supplement includes fourteen probiotic bacterial strains of Lactobacillus Spp, Bifidobacterium Spp., Bacillus coagulans, Saccharomyces boulardii, three prebiotics and Vitamin-B complex - B1, B2, B3, B6, B7, B9 in an enterosolvent cellulose capsule. The product includes supplementary substances: maltodextrin and magnesium stearate. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.
Placebo
The placebo product will have the same appearance as the active product and the same composition but without the live bacteria, prebiotics, and vitamin-B complex. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.

Locations

Country Name City State
Bulgaria University Hospital "St George" Plovdiv
Bulgaria University Hospital "Tsaritsa Yoanna - ISUL" Sofia
Bulgaria University Hospital for Pulmonary Diseases " St. Sofia" Sofia

Sponsors (1)

Lead Sponsor Collaborator
Neopharm Bulgaria Ltd.

Country where clinical trial is conducted

Bulgaria, 

References & Publications (10)

Barbut F, Meynard JL. Managing antibiotic associated diarrhoea. BMJ. 2002 Jun 8;324(7350):1345-6. doi: 10.1136/bmj.324.7350.1345. No abstract available. — View Citation

Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Front Microbiol. 2016 Jan 12;6:1543. doi: 10.3389/fmicb.2015.01543. eCollection 2015. — View Citation

Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010 Jul;105(7):1636-41. doi: 10.1038/ajg.2010.11. Epub 2010 Feb 9. — View Citation

Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015 Dec 22;(12):CD004827. doi: 10.1002/14651858.CD004827.pub4. — View Citation

Konstantinidis T, Tsigalou C, Karvelas A, Stavropoulou E, Voidarou C, Bezirtzoglou E. Effects of Antibiotics upon the Gut Microbiome: A Review of the Literature. Biomedicines. 2020 Nov 16;8(11):502. doi: 10.3390/biomedicines8110502. — View Citation

Mekonnen SA, Merenstein D, Fraser CM, Marco ML. Molecular mechanisms of probiotic prevention of antibiotic-associated diarrhea. Curr Opin Biotechnol. 2020 Feb;61:226-234. doi: 10.1016/j.copbio.2020.01.005. Epub 2020 Feb 19. — View Citation

Ouwehand AC. A review of dose-responses of probiotics in human studies. Benef Microbes. 2017 Apr 26;8(2):143-151. doi: 10.3920/BM2016.0140. Epub 2016 Dec 23. — View Citation

Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, Orel R, Shamir R, Vandenplas Y, van Goudoever JB, Weizman Z; ESPGHAN Working Group for ProbioticsPrebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):495-506. doi: 10.1097/MPG.0000000000001081. — View Citation

Szajewska H, Kolodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015 Nov;42(10):1149-57. doi: 10.1111/apt.13404. Epub 2015 Sep 13. — View Citation

Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015 Oct;42(7):793-801. doi: 10.1111/apt.13344. Epub 2015 Jul 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Antibiotic-Associated diarrhea (AAD) The incidence of AAD is defined as the number of subjects who experience at least one day of diarrhea compared to the total number of subjects enrolled in the given treatment arm. AAD is defined as 3 or more loose or liquid stools (types 5-7 according to Bristol Stool Scale [BSS]) over a period of 24 hours. By 21+2 days after completion of antibiotic dosing.
Secondary Severity of AAD Investigator will assess AAD severity using the following modified scale defining AAD as: severe: =7 unformed/loose/liquid stools; moderate: 5-6 unformed/loose/liquid stools; mild: a change in the stool pattern 3-4 unformed/loose/liquid stools a day. Investigator's assessment will take into consideration the 24-hour period presenting with the worst severity. By 21+2 days after completion of antibiotic dosing.
Secondary Duration of diarrhea Number of sequential days with diarrhea. Defined as the time until the first normalization of the stool form according to BSS: presence of one or two sequential normal stools, i.e. "soft and formed" or "hard and formed" - types 1-4 per BSS (or lack of stool) for a period of 24 hours. By 21+2 days after completion of antibiotic dosing.
Secondary Antibiotic-associated adverse experiences (abdominal pain, bloating, passing gas, nausea) Presence of abdominal pain, bloating, passing gass, nausea - Yes/No. By 21+2 days after completion of antibiotic dosing.
Secondary Visual-analogue scale for the gastrointestinal quality of life (VAS-QoL) Measured via Visual-analogue scale for the gastrointestinal quality of life. The subjects will answer the question: "To what extent the abdominal problems impact your quality of life?" This scale has numerical points from 0 to 100. "100" indicates THE WORST quality of life one can imagine, "0" indicates NO problems and THE BEST quality of life one can imagine. By 21+2 days after completion of antibiotic dosing.
Secondary Adverse events (AE) Incidence of mild (for example, self-resolving), moderate (for example, those requiring medical evaluation) and serious AEs (for example, events requiring lasting hospitalization) adverse events. By 21+2 days after completion of antibiotic dosing.
See also
  Status Clinical Trial Phase
Completed NCT03181516 - Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics Phase 2
Recruiting NCT03895593 - Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
Completed NCT00382304 - A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea Phase 2
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Terminated NCT02900196 - Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders N/A
Completed NCT01782755 - Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial Phase 2
Completed NCT06109740 - Probiotics For The Prevention of Antibiotics Associated Diarrhea in the Pediatric Intensive Care Unit N/A
Suspended NCT00591357 - Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy Phase 4
Completed NCT00700557 - Probiotics at the Treatment of Antibiotic Associated Diarrhea Phase 4
Active, not recruiting NCT03256708 - Prevention of Antibiotic-Associated Diarrhoea With Prolardii N/A
Completed NCT04321460 - Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults. Phase 3
Recruiting NCT05845073 - The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms N/A
Completed NCT02127814 - Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile N/A
Completed NCT01143623 - Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults Phase 2/Phase 3
Completed NCT00641199 - Probiotics for Prevention of Antibiotic-associated Diarrhea N/A
Completed NCT02462590 - Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial Phase 4
Terminated NCT01143272 - Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea Phase 3
Completed NCT03755765 - Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics Early Phase 1
Completed NCT05990972 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Antibiotic-associated Diarrhea N/A
Completed NCT02746198 - Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD) N/A